Published in Prostaglandins Leukot Essent Fatty Acids on August 01, 1992
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2013) 2.00
Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer (2000) 0.94
The immunobiology of prostanoid receptor signaling in connecting innate and adaptive immunity. Biomed Res Int (2013) 0.80
Editorial: TRPV1: how thymocytes sense stress and respond with autophagy. J Leukoc Biol (2012) 0.75
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol (2010) 1.45
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Systemic lupus erythematosus syndrome induced by pindolol. Br Med J (1979) 1.32
Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol (1987) 1.17
Cryoglobulinemic neuropathy: a pathological study. Ann Neurol (1980) 1.07
Allelic imbalance study of 16q in human primary breast carcinomas using microsatellite markers. Genes Chromosomes Cancer (1995) 1.05
Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol (2001) 1.04
The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens (2005) 1.03
Hepatitis-B vaccination in the elderly. J Infect Dis (1984) 1.03
Effect of lipoxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets. J Immunol (1985) 0.99
HL-A and silicosis. Am Rev Respir Dis (1977) 0.96
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol (2011) 0.96
Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer (2009) 0.92
Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells. Prostaglandins Leukot Essent Fatty Acids (2002) 0.90
Leukemia inhibitory factor: part of a large ingathering family. Int Rev Immunol (1998) 0.89
Metabolism of polyunsaturated fatty acids by mouse peritoneal macrophages: the lipoxygenase metabolic pathway. Agents Actions (1981) 0.89
Functional characterization of liver-associated lymphocytes in patients with liver metastasis. Gastroenterology (1993) 0.89
A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor. Cytokine (1997) 0.86
Effects of prostaglandin E2 and preincubation on lectin-stimulated proliferation of human T cell subsets. Cell Immunol (1982) 0.86
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry (1998) 0.85
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. Br J Cancer (2001) 0.83
Effect of LTB4 on the inhibition of natural cytotoxic activity by PGE2. Cell Immunol (1992) 0.81
High efficiency capillary column-gas chromatography mass spectrometry: analysis of the lipoxygenase pathway in eukaryot cells. Prostaglandins Leukot Med (1984) 0.81
Induction of suppressor cells from peripheral blood T cells by 15-hydroperoxyeicosatetraenoic acid (15-HPETE). J Immunol (1985) 0.81
HILDA/LIF urinary excretion during acute kidney rejection. Transplantation (1992) 0.81
Hydroperoxyeicosatetraenoic acids. Potent inhibitors of lymphocyte responses. Biochim Biophys Acta (1983) 0.81
Cyclooxygenase and lipoxygenase-like activity in Drosophila melanogaster. Prostaglandins (1986) 0.80
Immunogenicity of HILDA/LIF either in a soluble or in a membrane anchored form expressed in vivo by recombinant vaccinia viruses. Scand J Immunol (1993) 0.80
Thymocyte cyclic AMP and cyclic GMP response to treatment with metabolites issued from the lipoxygenase pathway. J Immunol (1985) 0.80
Stimulation of prostaglandin synthesis by the serum factor (FTS). Cell Immunol (1982) 0.80
Renal synthesis of leukaemia inhibitory factor (LIF), under normal and inflammatory conditions. Cytokine (2000) 0.79
Metabolic interactions between eicosanoids in blood and vascular cells. Biochem J (1989) 0.79
Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons. Cancer Immunol Immunother (1992) 0.79
Expression of the GST pi gene and response to tamoxifen therapy in locally advanced breast carcinomas. Ann N Y Acad Sci (1993) 0.79
Phenotypic heterogeneity of the OKM 1-positive lymphocyte population: reactivity of OKM1 monoclonal antibody with a subset of the suppressor/cytotoxic T-cell population. Cell Immunol (1982) 0.79
Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology (2001) 0.78
Effect of PGE2 on the cell surface molecule expression in PMA treated thymocytes. Immunol Lett (1998) 0.78
Effect of irradiation on human T-cell proliferation: low dose irradiation stimulates mitogen-induced proliferation and function of the suppressor/cytotoxic T-cell subset. Cell Immunol (1984) 0.78
Human monoclonal IgM with autoantibody activity against two gangliosides (GM1 and GD1b) in a patient with motor neuron syndrome. Clin Exp Immunol (1990) 0.77
In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates. Int J Cancer (2000) 0.77
Effect of arachidonic acid metabolites on thymocyte proliferation. Ann Inst Pasteur Immunol (1988) 0.77
[Inhibition of the lymphocyte response by metabolites released by the lipoxygenase of mouse macrophages]. C R Seances Acad Sci III (1981) 0.77
5-Lipoxygenase gene expression in the thymus. Thymus (1992) 0.76
In vitro generation of cytotoxic lymphocytes during noramidopyrine-induced agranulocytosis. Clin Immunol Immunopathol (1982) 0.75
Hypocomplementemia in keratoacanthoma. Arch Dermatol Res (1981) 0.75
Effect of prostaglandin E2 on cytotoxic activity and granzyme A protease release by murine adherent IL-2 activated killer cells. Immunobiology (1994) 0.75
In vitro study of platelets and circulating mononuclear cells of subjects presenting an intolerance to aspirin. Int Arch Allergy Immunol (1992) 0.75
Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas. Br J Cancer (1999) 0.75
Jacalin and artocarpin. J Immunol Methods (1992) 0.75
[Cold urticaria as a manifestation of infectious mononucleosis]. Presse Med (1983) 0.75
A simple in vitro test to evaluate biocompatibility of dialysis membranes. Nephrol Dial Transplant (1989) 0.75
Modulation of Fc gamma receptors on I cells and monocytes by 15 hydroperoxyeicosatetranoic acid. Prostaglandins Leukot Med (1984) 0.75
Heterogeneity of murine adherent interleukin-2-activated killer cells. Differential effect of prostaglandin E2 and forskolin. Cancer Immunol Immunother (1995) 0.75
[Immunofluorescence and determination of HL-A phenotypes in the study of Horton's disease]. Bull Soc Ophtalmol Fr (1979) 0.75
Effect of arachidonic acid metabolites on thymocyte tolerance. Ann N Y Acad Sci (1988) 0.75
Immunogenetics and hypertension. Lancet (1978) 0.75
[Paralysis of the 2 abducens nerves in non-excreting myeloma]. Rev Rhum Mal Osteoartic (1981) 0.75
Effect of PGE2 on thymocyte proliferation induced by Con A or IL-4 + PMA. Int J Immunopharmacol (1993) 0.75
Purification and characterization of monoclonal antibodies to alpha-linolenic acid. J Lipid Mediat (1992) 0.75
Juvenile melanoma after BCG vaccination. Dermatologica (1981) 0.75
[Adhesion of polynuclear cells to nylon fibers during filtration leukapheresis]. Rev Fr Transfus Immunohematol (1977) 0.75
[Relationship between maternal HL-A immunization and familial prognosis of haemolytic disease of the newborn due to Rh incompatibility]. Rev Fr Transfus Immunohematol (1975) 0.75
In vitro inhibition of human lymphocyte transformation by natural or synthetic prostaglandins. Prostaglandins Med (1979) 0.75
Cutaneous thickening in hyperthyroidism treated with radioactive iodine and sotalol. Lancet (1979) 0.75
Immunosuppression induced in vivo by 15 hydroxyeicosatetraenoic acid (15 HETE). Prostaglandins Leukot Med (1984) 0.75
Refolding of soluble leukemia inhibitory factor receptor fusion protein (gp 190 sol DAF) from urea. Mol Cell Biochem (1997) 0.75
Specific binding of 15 HETE to lymphocytes. Effects on the fluidity of plasmatic membranes. Prostaglandins Leukot Med (1984) 0.75
Inhibition of graft-versus-host reaction by treatment of immature thymocytes with eicosanoids. Prostaglandins Leukot Essent Fatty Acids (1998) 0.75
Effect of arachidonic acid metabolites on CR1 expression by B-lymphocytes. Int J Immunopharmacol (1989) 0.75
[Approaches to the immunological problems of leukocyte transfusions]. Nouv Rev Fr Hematol (1976) 0.75
In vitro generation of helper T cells and suppressor T cells that regulate the cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. Transplantation (1982) 0.75
[Clinical effects of the transfusion of leukocytes isolated by filtration from continuous flux]. Rev Fr Transfus Immunohematol (1977) 0.75
Effects of 15-hydroperoxyeicosatetraenoic acid on human lymphocyte sheep erythrocyte rosette formation and response to concanavalin A associated with HLA system. Eur J Immunol (1982) 0.75
In vitro production of human antigen presenting cells issued from bone marrow of patients with cancer. Hematol Cell Ther (1997) 0.75
[Critical study of the technique of leukopheresis by continuous flux filtration]. Nouv Rev Fr Hematol (1976) 0.75
HLA antigens and keratoacanthoma. Tissue Antigens (1981) 0.75
[Association of non-excreting myeloma and Paget's disease of bone]. Rev Rhum Mal Osteoartic (1981) 0.75
HLA phenotypes and cadmium blood level. Tissue Antigens (1979) 0.75
NZB/NZW F1 mouse nephritis and immune response are not changed by treatment with a 15-lipoxygenase derivative. Prostaglandins Leukot Essent Fatty Acids (1992) 0.75
Competitive polymerase chain reaction to quantify tumor cells in peripheral blood of patients with T(14;18)-bearing follicular non-Hodgkin's lymphoma: an exploratory study in 8 patients. Int J Cancer (1999) 0.75
Intra-operative electron beam radiotherapy and abdomino-pelvic surgery for cancer: influence on immunological parameters. Eur J Surg Oncol (1992) 0.75
[Skin fibrosis in hyperthyroidism treated by sotalol and radioactive iodine (author's transl)]. Ann Dermatol Venereol (1980) 0.75
[Immunology of aging]. Rev Med Interne (1983) 0.75
15-HETE "modulates" expression of C3b receptor (CR1) antigen on peripheral blood B-lymphocytes. Prostaglandins Leukot Med (1986) 0.75
Regulation by PGE2 of IL-2, IL-3 and IFN production by cortico-resistant thymocytes. Immunol Lett (1993) 0.75
Sequential production of leukaemia inhibitory factor by blood cell culture in patients with ARDS. Intensive Care Med (1998) 0.75
[Determination of a genetic marker predisposing to store cadmium in blood (author's transl)]. Ann Pharm Fr (1979) 0.75
One-year enzyme-linked immunosorbent assay follow-up of human interleukin for Da cells/leukemia inhibitory factor in blood and urine of 22 kidney transplant recipients. Transplantation (1994) 0.75
Radiobiological features of acute myeloblastic leukemia: comparison of self-renewal versus terminally differentiated populations. Int J Radiat Oncol Biol Phys (1994) 0.75